Korlym® selected Brand of the Year by Pharmaceutical Executive
Korlym® (mifepristone) 300mg Tablets has been selected by Pharmaceutical Executive as 2014 Brand of the Year, representing clinical and marketing achievements for an orphan-status rare disease drug. In selecting Korlym, Pharmaceutical Executive looked for a medicine that combines three strengths:
- A novel clinical profile
- An advance in the state of care for a difficult to treat condition, affecting a neglected cohort of patients
- Distinctive, multi-channel marketing geared to building community awareness around the disease, not the product
Since Korlym’s launch in 2012, Corcept has focused on building relationships with patients, endocrinologists and the Cushing’s community. Our dedicated Patient Advocate Program is one of the key programs that connects with and supports patients throughout their journey. More information for patients and prescribers is available at Korlym.com.
“Korlym is the first step toward a business that we are creating around a unifying scientific theme, which is to understand how excess cortisol levels influence the incidence and progression of not just one, but potentially dozens, of different conditions,” Corcept CEO Joe Belanoff told Pharmaceutical Executive.
Indications and Usage
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Important Limitations of Use
Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.